Intellia Therapeutics Inc is trading 5.1% down at $12.80 as investors continue to reassess the company's fundamentals following recent financial results and financing activities.
- The stock's decline is driven by post-earnings repositioning alongside investor concerns regarding cash burn and execution timelines.
- Shares remain under pressure from a dilution overhang following a late-April equity offering.
- Broader market weakness, particularly within the technology sector, is further weighing on the stock's performance today.